

Future of Cancer Health Economics -Equity Angles


Kosali Simon

INDIANA UNIVERSITY BLOOMINGTON

2018: Blacks died of cancer at a rate that is 12.2% higher than Whites

Black-White Cancer Mortality Gap varies a lot across states

Highest in Washington DC Lowest in Rhode Island Black-White 2018 Cancer Mortality Gap by State



Author created from sources on next slide. Age adjusted. Underlying cause of death is malignant neoplasms (ICD



State	Rate
DC	92.7
Wisconsin	37.5
Iowa	36.7
Utah	29.2
Illinois	25.1
Kansas	24.7
Missouri	20.5
Minnesota	20.2
Louisiana	19.3
California	19
Virginia	17.7
Pennsylvania	17.5
Texas	16.7
Nebraska	16.4
Oregon	16.3
Mississippi	16
Maryland	15.7
Michigan	13
North Carolina	12.6
Tennessee	11.1
Ohio	10.8
Arkansas	10.1

Georgia	7.5	
Connecticut	7.3	
Washington	6.6	
Alabama	6	
West Virginia	5.7	
Oklahoma	5	
Arizona	4.6	
Colorado	4.3	
Florida	4.1	
Hawaii	2.3	
Delaware	0.7	
New Mexico	0.3	
Kentucky	-1.8	
New York	-5.8	
Alaska	-13.7	
Massachusetts	-15.8	
Rhode Island	-24.4	

Source: Kaiser Family Foundation

https://www.kff.org/other/state-indicator/cancer-death-rate-by-raceethnicity/?activeTab=map¤tTimeframe=0&selecte

Notes: (1) NSD for Maine, North Dakota, South Dakota, N/A for Idaho, Montana, New Hampshire, Vermont, Wyoming

Age-adjusted rates per 100,000 U.S. standard population. Since death rates are affected by the population composition of a given area, age-adjusted death rates should be used for comparisons between areas because they control for difference in population composition.

Underlying cause of death is malignant neoplasms (ICD-10 codes: C00-C97). Excludes other: Native American, Alaska Native, Pacific Islander, and Asian All categories of race include people of Hispanic origin.

Race and Hispanic origin are reported separately on the death certificates. Sources

Centers for Disease Control and Prevention, National Center for Health Statistics. Underlying Cause of Death 1999-2018 on [CDC WONDER Online Database]

(http://wonder.cdc.gov/), released 2020.

Data are from the Multiple Cause of Death Files,

Accessed at http://wonder.cdc.gov/ucd-icd10.html on February 18, 2020. **Definitions**

NSD: Not Sufficient Data. Data are unavailable for confidentiality reasons or due

N/A: Data not available due to suppression constraints. For more information, ple



9.7

8.9

8.3


South Carolina

Nevada


Indiana

New Jersey


All Cancer Sites Combined Recent Trends in SEER Age-Adjusted Incidence Rates, 2000-2017 By Race/Ethnicity, Both Sexes, All Ages, Delay-adjusted Rates



Prostate Cancer Recent Trends in SEER Age-Adjusted Incidence Rates, 2000-2017 Male By Race/Ethnicity, All Ages, All Stages, Delay-adjusted Rates




Breast Cancer SEER 5-Year Age-Adjusted Incidence Rates, 2013-2017 By Race/Ethnicity, Female, Ages 50-64, All Stages





HR-/HER2- (Triple Negative) Breast Cancer (Female only) SEER 5-Year Age-Adjusted Incidence Rates, 2013-2017 Female By Race/Ethnicity, All Ages, All Stages



Created by https://seer.cancer.gov/explorer on Thu Dec 03 2020.

Cancers (Basel). 2018 Dec; 10(12): 514.

Published online 2018 Dec 14. doi: 10.3390/cancers10120514

PMCID: PMC6316530 PMID: 30558195

Racial Disparity and Triple-Negative Breast Cancer in African-American Women: A Multifaceted Affair between Obesity, Biology, and Socioeconomic Determinants

Sumit Siddharth* and Dipali Sharma*

Research Agenda 1:

Examine where trend disparities exist, Relate to advances in medical treatments Examine which populations appear to have missed out on progress for non-genetic reasons.





ORIGINAL RESEARCH published: 31 May 2019 doi: 10.3389/fonc.2019.00404 Trends and Patterns of Disparities in Burden of Lung Cancer in the United States, 1974-2015

Yu Jie Zhong¹¹, Yi Feng Wen²¹, Hai Ming Wong³, Guosheng Yin⁴, Ruitao Lin⁵ and Shuan Ying Yang¹*



Research Agenda 3: COVID-19, Cancer and Disparities





Did Progress Stall?

PMCID: PMC7299109

PMID: 32487802

Ann Surg. 2020 Jun 2: 10.1097/SLA.000000000003967.

Published online 2020 Jun 2. doi: <u>10.1097/SLA.000000000003967</u>

Are We Harming Cancer Patients by Delaying Their Cancer Surgery During the COVID-19 Pandemic?

Kiran K. Turaga, MD, MPH* and Saket Girotra, MD, MPH[†]



Methods and Data: Challenges and Opportunities

Challenges

- "close to experimental" design hard to achieve (Medicaid expansion, other policies that matter)
- Especially when medical-SES linked datasets few, small samples for disparities (eg Medical Expenditure Panel Survey) or race/ethnicity not well recorded

Opportunities

New data sources (electronic health records) improving in data quality & accessibility